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Abstract
Benzene, a ubiquitous environmental pollutant, causes acute myeloid leukemia (AML). Recently, through transcriptome
profiling of peripheral blood mononuclear cells (PBMC), we reported dose-dependent effects of benzene exposure on gene
expression and biochemical pathways in 83 workers exposed across four airborne concentration ranges (from,1 ppm to.
10 ppm) compared with 42 subjects with non-workplace ambient exposure levels. Here, we further characterize these dose-
dependent effects with continuous benzene exposure in all 125 study subjects. We estimated air benzene exposure levels in
the 42 environmentally-exposed subjects from their unmetabolized urinary benzene levels. We used a novel non-
parametric, data-adaptive model selection method to estimate the change with dose in the expression of each gene. We
describe non-parametric approaches to model pathway responses and used these to estimate the dose responses of the
AML pathway and 4 other pathways of interest. The response patterns of majority of genes as captured by mean estimates
of the first and second principal components of the dose-response for the five pathways and the profiles of 6 AML pathway
response-representative genes (identified by clustering) exhibited similar apparent supra-linear responses. Responses at or
below 0.1 ppm benzene were observed for altered expression of AML pathway genes and CYP2E1. Together, these data
show that benzene alters disease-relevant pathways and genes in a dose-dependent manner, with effects apparent at doses
as low as 100 ppb in air. Studies with extensive exposure assessment of subjects exposed in the low-dose range between
10 ppb and 1 ppm are needed to confirm these findings.
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Introduction
Benzene is a component of gasoline, and the starting ingredient
in the production of plastics and polymers via styrene; of resins and
adhesives via phenol; and, in the manufacture of nylon via
cyclohexane. It is toxic to the bone marrow and is associated with
various hematological cancers [1,2].
Multiple possible mechanisms of action are thought to be
involved in benzene toxicity [3,4,5,6]. Benzene exposure has been
shown to cause hematotoxicity [7], induce formation of protein
adducts [8,9], and increase the risk of leukemia [10], in a dose-
dependent manner. Linear or supra-linear dose-dependent effects
on lymphocyte counts and colony formation from myeloid stem
and progenitor cells and gene expression were reported at
relatively low levels of occupational exposure (#1 ppm to .
10 ppm) in exposed human populations [7,11,12]. Recently,
through transcriptome profiling of peripheral blood mononuclear
cells (PBMC), we reported dose-dependent effects of benzene on
gene expression and biochemical pathways in 83 workers exposed
to air benzene levels across four concentration ranges (from ,
1 ppm to .10 ppm), compared with 42 subjects not occupation-
ally exposed to benzene [13]. A 16-gene signature associated with
all levels of benzene exposure exhibited an apparently supra-linear
dose response. In addition, several immune response-related
pathways and the pathway associated with AML were significantly
modulated across several of the benzene dose ranges examined.
A deeper understanding of the dose-dependent, disease-relevant
human biochemical responses resulting from benzene exposure,
particularly at low doses, is important for next generation
approaches to human health risk assessment. Therefore, the goal
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of the current study was to further characterize the dose-
dependency of low-dose effects of benzene on genes and
biochemical pathways identified in our recent benzene-related
microarray analyses of PBMC [13]. Specifically, continuous data
for individual benzene exposure across all dose groups was used to
generate dose-response curves on a continuous scale. We used
predicted measures of benzene exposure in the group of subjects
with only ambient exposure to benzene. These subjects were
regarded as controls in the previous study but were, in fact, non-
occupationally exposed to benzene at varying, relatively low
environmental concentrations. Inclusion of data from these
individuals allowed us to examine more closely the responses in
the low dose (environmental) region of exposure. Using data from
all 125 study subjects, we applied non-parametric approaches,
based on the SuperLearner [14], to fit the responses of individual
gene expression as a function of benzene exposure. The use of
non-parametric approaches is particularly relevant here and in
epidemiological studies in general because it is impossible to know
the exact functional relationships among the variables such as gene
expression, dose from exposure, age, gender and smoking status of
the subject, cell counts etc. Non-parametric approaches make
minimal assumptions about these functional relationships and let
the observed data guide the choice of the best models using
rigorous statistical criteria (e.g., cross-validation [14]). The impli-
cation of making parametric assumptions is that if these
assumptions are untrue (which is almost certainly the case), the
results produced can be difficult to interpret. In the current study,
we developed novel non-parametric approaches to model the
responses in biochemical pathways of interest. We chose to model
the responses in 5 pathways, including the AML pathway and two
other pathways previously shown to be modified by benzene, and
two pathways presumably unrelated to benzene exposure. We also
employed the models to examine dose-response relationships in
the expression of a set of candidate genes known to be associated
with AML and with the metabolism of benzene.
The overall goals of this study were to estimate the benzene
exposure-response patterns of relevant gene expression and
biochemical pathways in a statistically rigorous, non-parametric
manner. This approach allowed us to identify consistencies in the
shapes of the resulting exposure-response curves and characterize
responses particularly in the low-dose region of exposure. Since
our original microarray data were generated from PBMCs which
comprise various cell types [15], including T lymphocytes (CD4
and CD8,65%), B cells (,15%), natural Killer cells (,10%), and
monocytes (,10%), we adjusted for changes in percentages of
these subtypes after benzene exposure in our analyses.
Materials and Methods
A brief overview of the data and methods used is given in
Figureoˆ 1.
Data Sets
Ethics statement. This study complied with all applicable
requirements of U.S. and Chinese regulations, including institu-
tional review board approval at the National Cancer Institute,
Bethesda, Maryland USA and the National Institute of Occupa-
tional Health and Poison Control, China CDC, Beijing. Partic-
ipation was voluntary, and written informed consent was obtained.
Study population, hematotoxicity, and gene expression
data. The overall molecular epidemiology studies investigating
occupational exposure to benzene [7,16] and the gene expression
data [13] upon which the analyses in the current study are based
were previously described. The gene expression data were
generated through transcriptome analysis by microarray of 125
subjects exposed to various levels of benzene. Among the 125
subjects, 42 were exposed to levels that were below the limit of
detection of the benzene monitors (0.04 ppm) used; 29 were
exposed to ,,1 ppm (average ,1 ppm and most individual
measurements ,1 ppm) benzene; 30 were exposed to ,1 ppm
(average ,1 ppm); 11 were exposed to levels between 5 ppm and
10 ppm; and 13 were exposed to levels $10 ppm. For each of the
exposed individuals in the study, benzene exposure was estimated
in terms of the average air-benzene level (in units of parts-per-
million). The exposure levels of the 42 subjects that were below the
limit of detection were estimated using unmetabolized urinary
benzene levels, as previously described [17]. Complete blood cell
counts, including counts for CD4 and CD8 T lymphocytes, B
lymphocytes, NK cells and monocytes, the major cell subsets of
PBMCs, were available for all the individuals analyzed by
microarray [7].
Biochemical Pathways
The biochemical pathways analyzed in this study were obtained
from the Kyoto Encyclopedia of Genes and Genomes (KEGG)
Pathway database [18,19,20]. The data for the set of genes within
each pathway and their associated interactions were downloaded
using the KEGG application programming interface (http://www.
kegg.jp/kegg/soap/). Five pathways were analyzed, including
three (AML, B-cell receptor signaling and Toll-like receptor
signaling) previously shown to be differentially modulated with
benzene exposure [13] and two (Steroid hormone biosynthesis and
Maturity onset of diabetes) presumably unrelated to benzene
exposure were not differentially modulated.
Linear Mixed Effect Models
We conducted variance components analysis using a linear
mixed model [21] to assess the proportion of total variation due to
differences between subjects, hybridizations, labels, and chips,
both before and after normalization [quantile normalization in the
Affy package [22] in R [23]]. For each probe, we estimated the
association between exposure level and expression level using a
mixed-effects model with random intercepts that accounted for
clustering by subject, hybridization, and label. The fixed effects in
our model included gender (1 = male, 0 = female), current smoking
status (1 = yes, 0 = no), age (in years, linear term), B cells, Natural
Killer (NK) cells, monocytes, and CD4 and CD8 cells (as counts
and included as linear terms). These were potential confounders of
associations (denoted by the vector of random variables, W)
between logarithm to the base 2 of gene expression (denoted by
the random variable, Y) and benzene exposure in five dose ranges
(denoted by the random variable, A). The model is thus given by,
Y
g
ijklm~b
g
0aizb
g
1zb
g
2 sexj
 
zbg3 smokej
 
zbg4 agej
 
zbg5 #B cellsj
 
zbg6 #NK cellsj
 
zbg7 #monocytesj
 
zbg8 #CD4 cellsj
 
zbg9 #CD8 cellsj
 
zmgj subjectð Þ
zmgk hybridizationð Þzmgl labelð Þzegijklm
ð1Þ
Y
g
ijklm denotes the log2 of the g
th gene expression, at the dose
ai, ai[ 0,1,2,3,4f g obtained from the jth subject after the kth
hybridization, lth labeling step in the microarray sample prepara-
tion and the mth chip. The bg parameters denote the fixed effects
associated with the respective covariates; the m parameters denote
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the random effects, and e denotes the normally distributed error
associated with the model. bg0, the fixed effect associated with
benzene exposure, is the parameter of interest in the model. We
fitted this mixed-effects model in R with the lmer function in the
lme4 package [24]. We also fit the mixed effects model without cell
counts as potential confounders as given in Equation (2).
Y
g
ijklm~b
g
0aizb
g
1zb
g
2 sexj
 
zbg3 smokej
 
zbg4 agej
 
zmgj subjectð Þzmgk hybridizationð Þzmgl labelð Þzegijklm
ð2Þ
We identified differentially expressed probes as those with a
statistically significant log-fold change (based on likelihood ratio
tests). We computed p-values adjusted for multiple testing by
controlling the false discovery rate (FDR) with the Benjamini-
Hochberg procedure [25], using the multtest package in R. These
FDR-adjusted p-values #0.05, the traditional experiment-wise
type I error rate, were considered significant.
Pathway Enrichment Analysis
We used a method known as ‘‘structurally enhanced pathway
enrichment analysis’’ (SEPEA_NT3) [26], which incorporates the
Figure 1. Overview of methods and analyses.
doi:10.1371/journal.pone.0091828.g001
Figure 2. Overlapping sets of genes determined by two linear
models. Two linear mixed models were used, a published model [13]
(see Equation (2)) and a modified version including counts of different
blood cell types as potential confounders of gene expression (see
Equation (1)). Differential expression was determined based on altered
fold changes in at least one of the four previously chosen dose ranges
of benzene exposure, with an FDR-adjusted p-value,0.05.
doi:10.1371/journal.pone.0091828.g002
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associated network information of KEGG (Kyoto Encyclopedia of
Genes and Genomes) human biochemical pathways [19,27,28].
Unlike traditional pathway enrichment methods that treat
pathways as sets of genes, SEPEA treats pathways as networks of
interacting proteins and/or enzymes. The genes corresponding to
the proteins in the signaling network are given more weight
according to whether they are at the receptor or the terminating
end of the pathway that typically signals for transcription in a
number of genes. Further, pathways where the perturbed genes
are close relative to each other on the associated network are
modeled as being more likely to be affected than pathways where
he perturbed genes occur further apart over the network. The
significance obtained by SEPEA_NT3 was based on 10000
randomizations.
Bootstrap-SuperLearner
The SuperLearner [14] method is a theoretically optimal
(relative to the so-called Oracle estimator) approach to model
selection in a data adaptive manner. This method requires a set of
different statistical learning algorithms that a user could consider
as being appropriate models of the data. SuperLearner then uses a
cross-validation-based loss function to estimate an optimal
combination of predictions from the different input algorithms to
produce model fits. The SuperLearner was used to fit
E Y=A~a,W~w
h i
where Y, A and W have the same meaning
as in the previous sections. Note in these analyses cell counts are
included as additional confounders. The fits were computed in the
SuperLearner package [29] implemented in the R statistical
environment [23] with a choice of a 10-fold cross-validation-based
loss function. The statistical learning algorithms used were random
forests [30], multivariate adaptive regression splines [31],, bagging
[32], Bayesian Generalized Linear Models [33], cforests
[34,35,36], neural networks [37], loess regression [38] and support
vector machines [39]. Different parameter settings for each of
these algorithms in their respective R packages were used (see
Figure 3. AML pathway-Principal Components-based response. The continuous fits in the two subplots use the first and second eigenvectors
(that are slightly modified, see Material and Methods section) respectively from the eigenvector matrix, Qps(n) given in Equation (5). The elements of
the individual eigenvectors are treated as the pathway response at the corresponding dose. The subscript p corresponds to the pathway under
consideration and superscript s to a given bootstrap sample. The bold red line correspond the mean parameter estimates across the bootstrap
samples and the bold black lines represent the corresponding 95% confidence intervals for the mean parameter estimates. The small vertical ticks on
the x-axis denote doses to which one or more subjects in the study were exposed and consequently the doses for which data for all covariates under
consideration were available. The three red ‘x’s above these ticks indicate the doses that there used to compare the rate of change of the marginal
effect of benzene exposure from 0.001 to 1 ppm air benzene to the corresponding rate from 1 to 10 ppm air benzene.
doi:10.1371/journal.pone.0091828.g003
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Table S1)In total there were 32 learning algorithms. The reader
interested in implementing the SuperLearner is referred to a
vignette (http://cran.r-project.org/web/packages/SuperLearner/
vignettes/SuperLearnerPresent.pdf) describing its implementation
in R.
In order to determine the variability of the SuperLearner mean
response estimates, a bootstrapping procedure was implemented.
Let n denote the number of subjects and NBS denote the number of
bootstrap samples. 1000 bootstrap samples were chosen in all
cases. Then for each bootstrap sample, n subjects are drawn
randomly with replacement and the mean response is then
estimated using the SuperLearner for each of the bootstrap
samples.
The marginal association of a given response (expression of gene
g) with the ith dose of benzene exposure (corresponding to A= a)
was then estimated by,
Ygs(n),i~Y
g
s(n)(a)~Y
g Ps(n)
 
(a)
~Ps(n) Q
g
s(n) a,Wð Þ{Qgs(n) 0,Wð Þ
 
~
1
n
X
j[s(n)
Q
g
s(n) a,Wj
 
{Q
g
s(n) 0,Wj
 
ð3Þ
Where s(n) represents a bootstrap sample, Ps(n) represents the
empirical distribution based on that sample, Q
g
s(n) a,Wð Þ the
Figure 4. AML pathway-Clusters of probes/genes. Hierarchical cluster of the probes in the AML pathway. The probes are clustered based on
the distance between the corresponding rows of the matrix, Xp. given in Equation (6). The figure is a visual representation of the distance matrix
between all the probes/genes in the pathway. The color of the (i,j)th position of the distance matrix is a measure of how close probes i and j are to
each other based on their response across the dose range. The color ranges from white to red. The closer the pair of probes is two each other, the
greater the intensity of red at the corresponding position. The dashed black lines correspond to boundaries of clusters of probes as determined by
the HOPACH algorithm [47].
doi:10.1371/journal.pone.0091828.g004
Gene Expression at Low-Levels of Benzene
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e91828
estimate of E Y
g
=A~a,W~w
h i
based on the SuperLearner
applied to s(n). A~0 represents doses #0.11 ppm. So for every
A~a(at which we calculated Ygs(n)(a), which were at points
separated 0.5 units apart on the log2 dose range), we get the
average difference of the predicted log2 gene expression value
(averaged across the W) and the predicted log2 gene expression
value if the sample represented very low to no exposure.
All the subjects with undetectable benzene exposure levels in
this study had predicted air benzene exposures less than 0.11 ppm.
Under certain assumptions [40,41], this parameter of interest in
Equation (3) also has also a simple causal interpretation, i.e., it
represents the mean log fold change of a given gene’s expression
due to exposure to a given dose relative to those with exposure less
than 0.11 ppm air benzene levels.
Biochemical Pathway Response
The derivation of the non-parametric estimate of the mean
response of a biochemical pathway with an outcome of interest in
the presence of confounders to its constituent gene expressions is a
statistical problem that does not appear to have been addressed
before in the literature. Examples of model-based approaches
include those in [42,43] who proposed generalized linear model-
based approaches to test for pathway association with a binary
clinical outcome and survival times. We propose two ideas to
provide summary responses of the expression of all the genes in a
biochemical pathway, both of which use non-parametric estimates
from the previously described Bootstrap-SuperLearner approach.
The first idea is based on using principal component analysis
(PCA) on the estimates from the SuperLearner of the expressions
of genes in the pathway. Principal component analysis has been
used in the past to model the pathway response [44,45]. The
change in expressions of the genes due to benzene exposure is
potentially confounded by other covariates in the study. Hence it
will not be correct to perform a direct analysis of the expressions of
the genes in the pathway in order to get a summary response.
Therefore, PCA is performed on the SuperLearner-based non-
parametric estimates of changes in gene expressions due to
benzene exposure. The second idea utilizes a clustering analysis of
these SuperLearner estimates in order to identify clusters of gene
expression responses and medoid genes or particular genes that
have responses that are representative of responses in the identified
clusters. Clustering analysis of gene expression data [46] has been
more or less standard for more than ten years.
Assume that the human biochemical pathways are identified by
indices in the set 1,2, . . . p, . . . ,Npath
 
Let Np denote the number
of probes corresponding to genes involved in the given pathway
identified by the index p. Nd is the number of points on the dose
range of the exposed individuals where the SuperLearner [14]
estimates are computed. Equally spaced points were chosen, 0.5
units apart on the logarithmic dose range.
In the first analysis, the dose-dependent responses were
estimated by the first and second principal components (or first
and second columns of the Q
p
s(n) eigenvector matrix) of the
covariance matrix, cov Xps(n)
 
created from the Np6Nd matrix,
X
p
s(n) obtained for the SuperLearner [14] estimate of the
parameters of interest (see Equations (4)-(6), where L
p
s(n) represents
diagonal matrix with the corresponding eigenvalues ordered in a
decreasing manner). This was done for each bootstrap sample, s.
Note,Y.s(n),i denotes the mean parameter of interest across all the
probes at the ith dose level.
X
p
s(n)~
Y1s(n),1    Y1s(n),Nd
..
. P ...
Y
Np
s(n),1    Y
Np
s(n),Nd
0
BBB@
1
CCCA ð4Þ
Xps(n)~
Y1s(n),1{Y
.
s(n),1    Y1s(n),Nd{Y
.
s(n),Nd
..
. P ...
Y
Np
s(n),1{Y
.
s(n),1    Y
Np
s(n),Nd
{Y.s(n),Nd
0
BBB@
1
CCCA ð5Þ
Table 1. Median and 95% confidence interval (CI) estimates of the rate of change of marginal effect of benzene exposure below
1 ppm (Bi,1/bg,1 – see equations (9) and (12)) and above 1 ppm (Bi,2/bg,2 - see equations (10) and (13)) and the change in absolute
rate of change of the marginal effects from below 1 ppm to above 1 ppm (Di/dg – see equations (11) and (14)) for the first two
principal components of the Acute Myeloid Leukemia pathway and six chosen genes of interest.
Bi,1/bg,1 Bi,2/bg,2 Di/dg
Pathway/Gene Median 95% CI Median 95% CI Median 95% CI
Acute Myeloid Leukemia: Principal
Component 1
0.333 (0.008, 0.394) 20.006 (20.016, 0.002) 0.328 (0.019, 0.380)
Acute Myeloid Leukemia: Principal
Component 2
0.106 (20.244,0.349) 20.024 (20.040,0.010) 0.108 (20.012,0.353)
RUNX1 0.07 (0.018, 0.158) 0.004 (20.008, 0.025) 0.063 (0.010, 0.151)
FLT3 20.079 (20.204, 20.012) 0 (20.005, 0.004) 0.078 (0.011, 0.202)
CEBPA 20.877 (21.11, 20.584) 0.03 (0.006, 0.069) 0.847 (0.561, 1.068)
LEF1 0.032 (20.035, 0.120) 20.009 (20.019, 20.002) 0.025 (20.008, 0.106)
CYP2E1 0.051 (20.004, 0.147) 20.002 (20.007, 0.002) 0.049 (0.002, 0.146)
CYP2F1 0.002 (20.033, 0.03) 20.001 (20.004, 0.001) 0.008 (20.001, 0.038)
doi:10.1371/journal.pone.0091828.t001
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cov Xps(n)
 
~ Xps(n)T
Xps(n)~Q
p
s(n)TL
p
s(n)Q
p
s(n) ð6Þ
Where
Q
p
s(n)~ q
1,p
s(n)    q
Np,p
s(n)
h i
ð7Þ
And q
1,p
s(n)    q
Np,p
s(n) are the Np eigenvectors corresponding to the
eigenvalues in the matrix L
p
s(n). Each of the Nd elements of the first
and second eigenvector was taken to represent the pathway
response at the corresponding dose. In order to make comparisons
of these eigenvectors across all bootstrap samples, two modifica-
tions were made to these eigenvectors. First, the first element of the
(first or second) eigenvector for each of the bootstrap samples was
normalized to zero. Second, if the sign of this normalized
eigenvector responses at 0.1 ppm was negative, and then the
negative of the elements of normalized eigenvector was plotted.
This can be done because any scalar multiple of the reported
eigenvector is an equally valid eigenvector for the given
eigenvalue. We denote these modified eigenvectors by q1,ps(n),q
2,p
s(n)
where for i = 1,2,
=
q1,ps(n)~ W
i,p
s(n)(a1)    Wi,ps(n)(aNd )
h i
ð8Þ
The pth pathway response at dose aj is given by W
i,p
s(n)(aj). Note by
definition W
i,p
s(n)(a1)~0.
Figure 5. Responses of selected genes associated with the leukemia disease process. Non-parametric model fits to the expression
response of the probes corresponding to six genes known to be associated with AML, with air-benzene concentrations in parts per million. Note the
responses here are log fold-changes in expression. The dot-dashed horizontal line at a log fold change value equal to zero indicates the no-effect
response. The gene names along with the corresponding probe id number on the microarray in parentheses are provided for each gene. The small
vertical ticks on the x-axis denote doses to which one or more subjects in the study were exposed and consequently the doses for which data for all
covariates under consideration were available. The three red ‘x’s above these ticks indicate the doses that there used to compare the rate of change
of the marginal effect of benzene exposure from 0.001 to 1 ppm air benzene to the corresponding rate from 1 to 10 ppm air benzene.
doi:10.1371/journal.pone.0091828.g005
Gene Expression at Low-Levels of Benzene
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For each bootstrap sample, these modified normalized eigen-
vector-based pathway response with dose is plotted as a smoothed
cubic spline using a smoothing parameter of 0.5. The plots were
made in the R statistical environment [23].
In the second analysis, the dose-dependent responses were
presented as a clustered (Np6Np) distance matrix between the
probes associated with the genes involved in the pathway. The
clustering was performed using the HOPACH algorithm [47] in
the package hopach [48] in the R statistical environment [23] where
the distance between the two Nd61 vectors, Y
i
. and Y
j
. associated
with a pair of probes, i and j is measured by the cosine distance
metric. Using this distance metric, HOPACH builds a hierarchical
cluster of trees by recursively partioning the data set. Note the
analyses here were performed on the matrix Xp. that represents the
average of X
p
s(n) over all the bootstrap samples.
Xp.~
Y1.,1    Y1.,Nd
..
. P ...
Y
Np
.,1    Y
Np
.,Nd
0
BBB@
1
CCCA ð9Þ
From the clustering analyses, we also presented the responses of
the genes identified as medoids for the six largest clusters as
identified by the HOPACH algorithm [47].
The advantage of the principal component analyses of the
pathway response is a one-picture summary response of the
variability of the estimates of mean response of the pattern among
a significant proportion of the genes in the pathway. However, this
picture does not inform whether the genes are being over or under
expressed at different levels of exposure. The plots of the medoid
genes provide the sign of response of these chosen genes.
Figure 6. Response of two Cytochrome p450 genes associated with benzene metabolism. Non-parametric model fits to the expression
response of the probes corresponding to two genes known to be associated with the metabolism of benzene, CYP2E1 and CYP2F1, with air-benzene
concentrations in parts per million. Note the responses here are log fold-changes in expression. The dot-dashed horizontal line at a log fold change
value equal of zero indicates the no-effect response. The gene names along with the corresponding probe id number on the microarray in
parentheses are provided for each gene. The small vertical ticks on the x-axis denote doses to which one or more subjects in the study were exposed
and consequently the doses for which data for all covariates under consideration were available. The three red ‘x’s above these ticks indicate the
doses that there used to compare the rate of change of the marginal effect of benzene exposure from 0.001 to 1 ppm air benzene to the
corresponding rate from 1 to 10 ppm air benzene.
doi:10.1371/journal.pone.0091828.g006
Gene Expression at Low-Levels of Benzene
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Estimates of the Change in the Rate of Change of
Response
Characteristics of the shapes of the dose-response curves were
obtained in terms of the change in the absolute rate of change of
marginal effect of benzene exposure from below 1 ppm to above
this level. For the two pathway responses (i = 1,2), the rate of
change of the marginal effect response below 1 ppm for the
bootstrap sample s(n) is estimated by,
Bi,1s(n)~
W
i,p
s(n)(a2){W
i,p
s(n)(a1)
a2{a1
ð10Þ
Where a2~1ppm and a1~0:001ppm, W
i,p
s(n)(aj) is as given in
Equation (8). The rate of change of response above 1 ppm by,
Bi,2s(n)~
Wi,ps(n)(a3){W
i,p
s(n)(a2)
a3{a2
ð11Þ
Where a3~10ppm and the estimate of the change in the absolute
rate of change of response,Dis(n) is chosen to be
Dis(n)~DB
i,1
s(n)D{DB
i,2
s(n)D ð12Þ
Analogously the estimates of the change in the absolute rate of
change of gene, g level responses, dgs(n) are given by,
bi,1s(n)~
Y
i,p
s(n)(a2){Y
i,p
s(n)(a1)
a2{a1
ð13Þ
bi,2s(n)~
Yi,ps(n)(a3){Y
i,p
s(n)(a2)
a3{a2
ð14Þ
dis(n)~Db
i,1
s(n)D{Db
i,2
s(n)D ð15Þ
Where Yi,ps(n)(aj) is given by Equation (3). The bootstrap samples of
Dis(n) and d
g
s(n) are used to estimate the 95% confidence intervals
for Di and dg. Significant positive values of these estimates suggest
supralinearity of the marginal effects of benzene exposure while
significant negative values suggests sublinearity of these effects
between 0.001 ppm and 10 ppm benzene levels.
Results
Predicted Air Benzene Exposure Levels in Non-
occupationally Exposed Subjects
The air benzene exposure levels for the 42 control subjects [13]
were predicted from their urinary unmetabolized benzene levels
[17]. For 8 of the control subjects, exposure predictions were
unavailable and these subjects were excluded from the non-
parametric analyses. The predicted benzene exposure levels
ranged from 1.461024 ppm to 0.11 ppm, with 32 subjects
predicted to have levels below 0.009 ppm.
Peripheral Blood Cell Counts as Potential Confounders of
Gene Expression
Two linear mixed models of gene expression as a function of air
benzene exposure were fitted to the data from 125 subjects who
had been exposed to benzene in four previously chosen
concentration ranges, ,,1 ppm, ,1 ppm, .5 ppm and ,
10 ppm, and $10 ppm,or were controls. One of the models was
identical to that recently reported by us [13] and included the
gender, age and smoking status of the subjects as potential
confounders of gene expression. The second model was the same
but also included the measured counts of different cell types
present in the PBMC as additional confounders (see Equation (1)).
The estimates of the fixed effects of this model are given in Table
S2. The distribution of the estimates of the intra-class coefficients
for each of the random effects do not change when moves from a
model that does not include the PBMCs to one that does (see
Figure S1). As shown in the Venn diagram in Figureoˆ 2, there was
a significant overlap (2183 genes) between the sets of genes
identified as differentially expressed (FDR-adjusted p-value ,0.05)
by each linear model. Fisher’s exact test estimated a p-value ,
2.2610216 for the null hypothesis stating the independence
between genes declared differentially expressed by the two linear
models. When cell counts were incorporated as potential
confounders, 821 out of 3004 genes identified as differentially
expressed in the original model were no longer significant, while
an additional 388 genes were found to be significant. There were
also no major differences in the pathway enrichment values for all
the KEGG human pathways using results from either model
(Table S3). Pathway enrichment analyses were also done on the
sets of genes that were commonly identified as differentially
expressed genes (2183 genes) and uniquely by either of the models
(821 or 388 genes) (see Table S3). The pearson correlation
between the log10 transformed p-values across pathways for the set
of genes uniquely identified by the model that did not incorporate
cell count with the corresponding p-values for the set of genes
commonly identified by both models is 0.06 (p-value = 0.32). The
pearson correlation for the pathway p-values using the set of genes
uniquely identified by the model that incorporated cell count with
corresponding p-values for commonly identified set of genes is
0.22 (p-value = 0.0005).
Biochemical Pathway-based Responses
A dose-specific parameter of interest (defined in Equation (3))
was estimated non-parametrically for the expression of each
probe/gene in the KEGG AML, B-cell receptor signaling, Toll-
like receptor signaling, Steroid hormone biosynthesis, and
Maturity onset of diabetes pathways, at points equally spaced
0.5 units apart on the logarithmic dose range. For a given gene at a
chosen dose, this parameter is the expected log fold-change in the
expression of the gene at that dose relative to the mean expression
of subjects exposed to levels below 0.11 ppm. The parameters
were estimated using the SuperLearner [14] that used 32 learning
algorithms and the sampling distribution of these parameters was
estimated via a bootstrapping procedure in which the parameters
are re-estimated using random selection (with replacement) of the
125 subjects. The bootstrapping procedure was repeated 1000
times.
The first and second principal components of the estimated
parameters for all genes in the AML pathway, evaluated across the
entire study dose range, are shown in Figureoˆ 3. Together, these
two principal components captured 86% of the dose-dependent
variation in expression of genes in the AML pathway. The first
and second principal components of the dose-response parameters
for all genes in the B-cell receptor signaling, Toll-like receptor
signaling, Steroid hormone biosynthesis and Maturity onset of
diabetes pathways are shown in figure S2, respectively. Visually,
the mean estimates of the first principal components of the
responses look similar across the five chosen pathways and suggest
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supra-linear responses. This is quantitatively reinforced by the fact
that the estimates of the change in the absolute rate of change of
marginal effect of benzene exposure from below 1 ppm to above
1 ppm for the first principal component of each of the five
pathways (see Equation (12)) are significantly positive (p-value ,
0.05) (see Table 1 and Table S4). There are suggestions of
responses at doses below 0.1 ppm, and exposures of around
0.1 ppm and 1 ppm appear to be inflection points for at least three
(AML, Toll-like receptor signaling and Maturity Onset of
Diabetes) of the five pathways. The mean estimates of the second
principal components are also similar across the five pathways,
with exposures around 0.1 ppm appearing to represent inflection
points for these responses. The responses of the probes in the
pathway were clustered using HOPACH [49] (Figureoˆ 4 and
figure S3), and the results confirm that many sets of genes exhibit
similar response patterns.
Expression-based Responses of Chosen Genes of Interest
A small set of genes was chosen based either on their known
association with leukemogenesis or because they code for enzymes
putatively associated with the metabolism of benzene to its toxic
metabolites. In the first class, oncogenes (RUNX1, FLT3, LEF1)
or tumor suppressors (RUNX1, CEBPA) implicated in leukemia
[50,51,52,53,54,55] were selected. RUNX1 has been identified as
both an oncogene and a tumor suppressor gene [56,57]. The
responses (in terms of log-fold changes) of these genes are plotted
in Figureoˆ 5. Among these genes, RUNX1, LEF1 and CEBPA
were differentially expressed (FDR,0.05) based on the linear
model in Equation (1) across four binned dose ranges. Based on
the position of the line corresponding to no change (i.e., log fold
change equals zero) relative to the 95% confidence interval of the
estimated fold change at a chosen dose, the expressions of FLT3
and CEBPAare all down regulated on exposure to levels of air
benzene above around 0.1 ppm. RUNX1, FLT3 and CEBPA
display profiles that are supralinear as captured by the significant
positive values of the change in the absolute rate of change of
marginal effect of benzene exposure from below 1 ppm to above
1 ppm (see Equation (15) and Tableoˆ 1). The responses of the
expression of two genes, CYP2E1 and CYP2F1 (enzymes
putatively associated with the metabolism of benzene to its toxic
metabolites), are shown in Figureoˆ 6. CYP2E1 is known to be
involved with the metabolism of benzene [58,59,60] and CYP2F1
has been hypothesized to be associated with benzene metabolism
[3]. CYP2E1 expression was increased at levels of air benzene
concentration as low as 0.01 ppm, while expression of CYP2F1
was largely unaltered.CYP2E1, but not CYP2F1, was found to be
differentially expressed (FDR,0.05) based on the linear model in
Equation (1) across four binned dose ranges. The dose-response of
CYP2E1 is supralinear (see Equation (15) and Tableoˆ 1).
Discussion
The analyses in this study sought to further characterize the
dose-dependency of changes in gene expression associated with
occupational exposure to benzene that we reported recently [13]
and to extend them into the ambient environmental range by
estimating exposures for the non-occupationally exposed ‘con-
trols’. We further extended the analyses to include PBMC subset
cell counts as potential confounders of expression.
Significant overlap was seen for the majority of genes identified
as differentially expressed using the parametric linear models,
regardless of whether or not PBMC cell counts were incorporated
as potential confounders. Genes that did not remain differentially
expressed after incorporation of cell counts as confounders could
be indirectly related to benzene-induced cell count decrements.
One plausible example is the CD44 gene; it encodes a marker for
CD4 and CD8 cells, both of which were reduced in number in
benzene-exposed individuals [7]. However, the estimation of
additional parameters in the model to incorporate cell counts as
confounders resulted in loss of statistical power to identify genes as
differentially expressed. Conversely, the incorporation of cell
counts in the model may improve the model fit and subsequently
increase the ability of the model to detect true dose-specific
changes in gene expression. This is partly suggested by the
significant but relatively small correlation (0.22) of the pathway p-
values using the set of genes uniquely identified by the model
incorporating cell counts with the pathway p-values using the set of
genes commonly identified by both models. In either case, the fact
that a significant overlap was observed implies that the majority of
the changes in gene expression are not directly mediated through
the hematotoxicity of benzene.
We defined the dose-dependent effects on gene expressions as
our parameters of interest as a marginal effect of benzene
exposure. The definition of the parameter in dose-response studies
of this kind is to the best of our knowledge novel in the toxicology
literature – that is, as the marginally adjusted curve of the mean
outcome versus exposure. This is extremely important in itself,
because when measuring how dose-response affects a population,
one should estimate a population level dose response parameter.
However, what is typically done is to estimate the dose response in
a parametric or semi-parametric model, where the resulting curve
represents potentially a different curve for every covariate group.
To avoid this problem, the predominant approach is to simply
make the simplifying, but erroneous assumption, that all groups
have the same dose response curve). We wanted to make no such
bias inducing assumptions, and so we estimated these dose
response curves in a nonparametric model, using optimal data-
adaptive methods (SuperLeanrer [14]) for estimating the relation-
ship of expression to exposure and the confounders. Thus, we have
approached a problem typically approached using ad hoc
methods, based on arbitrary statistical modeling assumptions,
and used methods based on what is truly known about the
relationship of expression to the covariates including exposure,
that is nearly nothing, and derived optimal (the SuperLearner is
not ad hoc, but based on the theorem of the Oracle Inequality
[14]) estimators respecting the underlying knowledge. We use a
bootstrapping approach in order to estimate the sampling
variability of these estimates. Note that these estimates are
essentially derived from data-adaptive methods in a very large
(nearly non-parametric) model, where the number of assumptions
made about the probability generating distributions is minimal,
particularly as compared to standard approaches using parametric
models.
The five pathways chosen for analyses were selected based on
the results to our earlier analyses [13] with the same gene
expression data on the same set of KEGG [19,27,28] human
pathways. Ideally, we should have performed these analyses while
being agnostic to the potential biochemical pathways being
targeted. This would mean analyzing all 22177 probes on the
microarray by the proposed non-parametric methodology. How-
ever, we chose to analyze the 5 pathways in part because the
proposed non-parametric methodology requires significant com-
puting power- one bootstrap sample run of the dose response of a
given probe/gene using the SuperLearner [14] that ran 32
learning algorithms took around 20 seconds to run on a 4-core
linux machine with around 1 GHz cpu and 16 GB RAM. We
should note that the associations of benzene exposure are being
made with biochemical pathways of diseases (AML and Maturity
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Onset of Diabetes) and not with the diseases directly. These
biochemical pathways represent a summary of the literature on the
specific disease pathogenesis. Further the exact definition of a
specific biochemical pathway in terms of its constituents and
associated interactions will be consistent though not the same
across different pathway databases. Therefore our choices of the
pathways were from the same set of pathways analyzed before
albeit with the same data – our goal here being a better
characterization of the dose responses over the entire continuous
range of exposures. The AML pathway was of particular interest
because of the established association of benzene exposure with
leukemia incidence [1,2]. The other two pathways (B-cell receptor
and Toll-like receptor signaling) were randomly chosen from the
set of pathways which displayed significant dose response over the
range of benzene exposures. Similarly the Steroid Hormone
Biosynthesis and Maturity onset of diabetes pathways were chosen
from the list of pathways that did not display statistical significant
responses.
The mean estimates of first and second principal components of
the dose-response relationships determined by the our method
method for all genes in the five chosen pathways (AML, B-cell
receptor signaling, Toll-like receptor signaling, Steroid hormone
biosynthesis and Maturity onset of diabetes) showed apparent
similarities and similar inflection points were observed for several
of the pathways. Since two of the analyzed pathways, Steroid
hormone biosynthesis and Maturity onset of diabetes, are
presumably unrelated to benzene, the noted similarities in
response implies that the changes in expression of genes in these
pathways are real effects though they were not large enough to
provide statistical significance for modulation at the pathway level.
Consistency of the shapes of the responses across the five chosen
pathways may be a consequence of the correlation among gene
expression levels on a system-wide basis through coordinated
transcriptional regulation. However, analyses of the binding sites
in the promoter regions of the differentially expressed genes (across
doses, as determined by the linear model in Equation (1)) did not
reveal enrichment of any transcription factor binding sites (data
not shown).
Together, these similarities support the plausibility of the
observed supra-linear dose-responses. In addition supralinearity
is quantitatively supported by positive values of the parameter that
captures the change in the absolute rate of change of marginal
effect of benzene exposure from below 1 ppm to above 1 ppm (see
Equations (12) and (15), Tableoˆ 1). This adds to the literature of
observed supra-linear responses associated with benzene exposure
– see for example the response of benzene oxide-albumin adduct
formation with benzene exposure [61], the dose related produc-
tion of benzene metabolites [17] and the relative risk of leukemia
with benzene exposure [10].
Our statistical tests for supralinearity are based on comparing
the rate of change of the marginal effect of exposure below 1 ppm
(0.001–1 ppm) benzene to the rate of change of this marginal
effect above 1 ppm (1–10 ppm). We don’t perform statistical tests
for supra-linearity of the overall dose response curve. Testing for
supra-linearity is a very subtle issue, since any data adaptive
approach, compared to some model in a goodness of fit test, will
always win out asymptotically (any null model will be not perfectly
right, so as sample size grows, and the data-adaptive approach will
favor more highly parameterized models to create a better fit, any
improvement over the null becomes statistically significant). Thus,
any conclusion made from a test in this context is dubious, since
the asymptotic p-value will always go to 0. Therefore, we used an
approach based on confidence intervals of the overall dose-
response curve, which do not have this particular pathology.
Several genes of interest were chosen for examination based on
their association with leukemogenesis or benzene metabolism. The
observed significant decrease in CEBPA expression at benzene
levels of around 0.1 ppm may be important in light of the fact that
reduced CEBPA gene expression has been associated with
increased risk of leukemia [55]. Changes in the expression of
CYP2E1 were observed at levels of air benzene concentration as
low as 0.01 ppm. As benzene metabolism occurs principally in the
liver [62] and also in the lung [63,64], with secondary metabolism
occurring in the bone marrow [65,66,67], the implication of
altered expression of CYP2E1 in peripheral blood is not entirely
clear.
In order to permit phenotypic anchoring of the observed dose-
dependent changes in gene expression, the responses of counts of
B-cells, white blood cells and the ratio of the counts of CD4 cells to
CD8 cells, are estimated using the Bootstrap-SuperLearner
approach (data not shown). The observed decreases in these cell
counts have been previously reported [7]. Mean changes in gene
expression can thus be associated with corresponding changes in
mean cell counts. For example, a 0.75 expected fold change of
CEBPA gene expression at 1 ppm of air benzene would be
associated with a mean decrease of 600 white blood cells/ml or a
decrease of 0.2 in the ratio of CD4 to CD8 cells.
In summary, this work presents a new approach, which is the
combination of the choice of a statistical parameter to be
estimated, the methods used to estimate the data generating
distribution (our parameter is only a targeted part of that
distribution), and rigorous and robust methods for deriving
inference, applied to the scientific question of estimating the
dose-dependent biological responses resulting from exposure to
benzene in the air. This work extends our previous analyses of
benzene-induced differential gene expression in occupationally
exposed workers and demonstrates that the differential expression
of the majority of genes is independent of changes in cell counts of
various blood cell types; that many differentially expressed genes
and disease-relevant pathways display an apparently supra-linear
response; and, that benzene alters these pathways and genes at
exposure levels as low as 0.1 ppm. However, limitations in the
statistical models and in the interpretation of some of these
findings suggest that studies with a larger number of samples from
individuals exposed to benzene in the low-dose range between
0.01 and 1 ppm are needed to clarify and confirm our
interpretations. More precise exposure measurement and/or
estimation in the low-dose region are needed to clarify the nature
of the dose-response relationship of gene alteration in the low-dose
range.
Supporting Information
Figure S1 Distribution of intra-class coefficients of the
chip, subject, labeling and hybridization random ef-
fects.
(PDF)
Figure S2 Pathways-Principal Components-based Re-
sponse. Non-parametric model fits to the marginal association of
the expression of the probes corresponding to the genes involved
in the a. B-cell receptor signaling, b.Toll-like receptor signaling, c.
Steroid Hormone bio-synthesis and d.Maturity onset of diabetes
pathways with air-benzene concentrations in parts per million.
The continuous fits in the two subplots use the first and second
eigenvectors (that are slightly modified, see Material and Methods
section) respectively from the eigenvector matrix, Q
p
s(n) given in
Equation (5). The elements of the individual eigenvectors are
treated as the pathway response at the corresponding dose. The
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subscript p corresponds to the pathway under consideration and
superscript s to a given bootstrap sample. The bold red line
correspond the mean parameter estimates across the bootstrap
samples and the bold black lines represent the corresponding 95%
confidence intervals for the mean parameter estimates. The small
vertical ticks on the x-axis denote doses to which one or more
subjects in the study were exposed and consequently the doses for
which data for all covariates under consideration were available.
The three red ‘x’s above these ticks indicate the doses that there
used to compare the rate of change of the marginal effect of
benzene exposure from 0.001 to 1 ppm air benzene to the
corresponding rate from 1 to 10 ppm air benzene.
(PDF)
Figure S3 Pathways-Clusters of probes/genes. Non-
parametric model fits to the marginal association of the expression
of the probes corresponding to the genes involved in the a. B-cell
receptor signaling, b.Toll-like receptor signaling, c. Steroid
Hormone bio-synthesis and d.Maturity onset of diabetes pathways
with air-benzene concentrations in parts per million. The probes
are clustered based on the distance between the corresponding
rows of the matrix, Xp. given in Equation (6). The figure is a visual
representation of the distance matrix between all the probes/genes
in the pathway. The color of the (i,j)th position of the distance
matrix is a measure of how close probes i and j are to each other
based on their response across the dose range. The color ranges
from white to red. The closer the pair of probes is two each other,
the greater the intensity of red at the corresponding position. The
dashed black lines correspond to boundaries of clusters of probes
as determined by the HOPACH algorithm [47].
(PDF)
Table S1 List of supervised learning algorithms.
(XLSX)
Table S2 Fixed effects estimates for the mixed model in
Equation (1).
(XLSX)
Table S3 p-Values for KEGG pathways. The p-values were
computed using the SEPEA_NT3 procedure [26] based on results
of differential from expression (in at least one of the four benzene
exposure groups) from the linear mixed models with (L1) and
without (L0) using the blood cell counts as potential confounders of
gene expression. Also listed are the p-values obtained the KEGG
pathway enrichment using genes commonly identified by both
models, unique to the model (L0) and unique to the model (L1).
(XLSX)
Table S4 Median and 95% confidence interval (CI)
estimates of the rate of change of marginal effect of
benzene exposure below 1 ppm (Bi,1/bg,1– see equations
(10) and (13)) and above 1 ppm (Bi,2/bg,2 - see equations
(11) and (14)) and the change in absolute rate of change
of the marginal effects from below 1 ppm to above
1 ppm (Di/dg – see equations (12) and (15)) for the first
two principal components of the for the B-cell receptor
signaling, Toll-like receptor signaling, Steroid hormone
synthesis and Maturity onset of diabetes pathways.
(XLSX)
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